Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John Crown

Showing results (41-50 of 202) with videos related to

Pageof 21
Sort By:
Breast (Edinburgh, Scotland)|August 14, 2016
Validated biomarkers: The key to precision treatment in patients with breast cancerMichael J Duffy, Norma O'Donovan, Enda McDermott, et al.
Nutrition and Cancer|December 10, 2022
Vitamin D Supplementation: Does It Have a Preventative or Therapeutic Role in Cancer?Michael J Duffy, Maeve Mullooly, Kathleen Bennett, et al.
Cancer Biology & Therapy|September 13, 2013
Global analysis of serum microRNAs as potential biomarkers for lung adenocarcinomaSweta Rani, Kathy Gately, John Crown, et al.
Seminars in Cancer Biology|August 4, 2020
Targeting p53 for the treatment of cancerMichael J Duffy, Naoise C Synnott, Shane O'Grady, et al.
Breast Cancer Research and Treatment|September 21, 2019
COTI-2 reactivates mutant p53 and inhibits growth of triple-negative breast cancer cellsNaoise C Synnott, David O'Connell, John Crown, et al.
International Journal of Cancer|March 25, 2017
Neuromedin U alters bioenergetics and expands the cancer stem cell phenotype in HER2-positive breast cancerVanesa G Martinez, John Crown, Richard K Porter, et al.
Expert Opinion on Therapeutic Targets|August 3, 2014
cMET in triple-negative breast cancer: is it a therapeutic target for this subset of breast cancer patients?Patricia B Gaule, John Crown, Norma O'Donovan, et al.
Cancer Biology & Therapy|April 27, 2016
The ADAMs family of proteases as targets for the treatment of cancerMaeve Mullooly, Patricia M McGowan, John Crown, et al.
International Journal of Molecular Sciences|January 25, 2025
Pre-Clinical Rationale for Amcenestrant Combinations in HER2+/ER+ Breast CancerAmira F Mahdi, Niall Ashfield, John Crown, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 2012
Reversible posterior leukoencephalopathy syndrome and bevacizumab in breast cancerFrancesco Sclafani, Gullo Giuseppe, Janusz Mezynksi, et al.
Pageof 21

Showing results (41-50 of 202) with videos related to

Sort By:
Pageof 21
Breast (Edinburgh, Scotland)|August 14, 2016
Validated biomarkers: The key to precision treatment in patients with breast cancerMichael J Duffy, Norma O'Donovan, Enda McDermott, et al.
Nutrition and Cancer|December 10, 2022
Vitamin D Supplementation: Does It Have a Preventative or Therapeutic Role in Cancer?Michael J Duffy, Maeve Mullooly, Kathleen Bennett, et al.
Cancer Biology & Therapy|September 13, 2013
Global analysis of serum microRNAs as potential biomarkers for lung adenocarcinomaSweta Rani, Kathy Gately, John Crown, et al.
Seminars in Cancer Biology|August 4, 2020
Targeting p53 for the treatment of cancerMichael J Duffy, Naoise C Synnott, Shane O'Grady, et al.
Breast Cancer Research and Treatment|September 21, 2019
COTI-2 reactivates mutant p53 and inhibits growth of triple-negative breast cancer cellsNaoise C Synnott, David O'Connell, John Crown, et al.
International Journal of Cancer|March 25, 2017
Neuromedin U alters bioenergetics and expands the cancer stem cell phenotype in HER2-positive breast cancerVanesa G Martinez, John Crown, Richard K Porter, et al.
Expert Opinion on Therapeutic Targets|August 3, 2014
cMET in triple-negative breast cancer: is it a therapeutic target for this subset of breast cancer patients?Patricia B Gaule, John Crown, Norma O'Donovan, et al.
Cancer Biology & Therapy|April 27, 2016
The ADAMs family of proteases as targets for the treatment of cancerMaeve Mullooly, Patricia M McGowan, John Crown, et al.
International Journal of Molecular Sciences|January 25, 2025
Pre-Clinical Rationale for Amcenestrant Combinations in HER2+/ER+ Breast CancerAmira F Mahdi, Niall Ashfield, John Crown, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 2012
Reversible posterior leukoencephalopathy syndrome and bevacizumab in breast cancerFrancesco Sclafani, Gullo Giuseppe, Janusz Mezynksi, et al.
Pageof 21